Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 2060

Next Previous
Drug Profile

MK 2060

Alternative Names: MK-2060

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies; Urologics
  • Mechanism of Action Factor XI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Renal failure; Thrombosis

Most Recent Events

  • 18 Apr 2025 Merck Sharp & Dohme completes phase I safety, pharmacokinetics, and pharmacodynamics trial (In volunteers (IV, infusion) in the US (NCT06582602)
  • 20 Mar 2025 Discontinued - Phase-II for Thrombosis (Prevention) in Sweden, Russia, Romania, Puerto Rico, Portugal, Italy, Greece, Czech Republic, Germany, Canada, Bulgaria, Australia, Brazil, Argentina (IV), before March 2025 (Merck pipeline, March 2025)
  • 31 Dec 2024 Discontinued - Phase-I for Renal failure (In the elderly, In adults) in Japan (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top